
|Articles|November 1, 2004
Intravesical agent shows some promise in treating IC
Whistler, British Columbia, Canada-Intravesical hyaluronic acid (Cystistat) appears to be a simple, quick therapy for reducing pain, frequency, and nocturia in patients with interstitial cystitis, according to Austrian and Canadian researchers. The agent may also improve radiation-induced cystitis and reduce bacterial cystitis recurrences in patients with recurrent urinary tract infections, said Marc Riviere, MD, senior vice president at Belleville, Ontario-based Bioniche Life Sciences Inc., who presented a series of pilot studies at the Canadian Urological Association annual meeting.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
2
FDA approves sildenafil oral film for men with erectile dysfunction
3
Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC
4
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
5






